The Therapeutic Effects of Psychedelics: 2A or Not 2A?-Part 2
Some studies reveal that serotonin 2A receptor activation may not be necessary for the potential therapeutic effects of psychedelics.
Depression
Fear of Death Impacts Quality of Life-How Psychedelics Can Help
Researchers suggest that the benefits of psychedelic treatment are mediated by a reduction in death anxiety and existential distress.
The Therapeutic Effects of Psychedelics: 2A or Not 2A? – Part 1
The serotonin 2A receptor is a major player in the psychedelic response, but it may not be the only one involved.
Glutamate’s Role in Rapidly-Acting Antidepressants
Despite differing pharmacodynamics, ketamine and serotonergic psychedelics may share downstream effects crucial to their rapid and sustained antidepressant activity.
Same But Different: Antidepressant Mechanisms of Psilocybin and Ketamine
Ketamine and psilocybin both exert rapid antidepressant effects. Could these effects be explained by a common mechanism that promotes neurogenesis?
Mouse Study Reveals New Details on Psilocybin’s Rewiring of the Brain
Changes in structural neuroplasticity start within 24 hours, are enduring, and may not be solely dependent on 5-HT2A.
Active vs. Passive Coping Distinguishes Antidepressants and Psychedelics
5-HT1AR vs. 5-HT2AR signaling and the treatment of depression.
Real-World Research in Psychedelic Science
Researchers see value in a naturalistic approach to psychedelic studies.
The Psilocybin vs. Escitalopram Trial – Part 2
A deep dive into the strengths and limitations of the trial.
The Psilocybin vs. Escitalopram Trial – Part 1
Was psilocybin really effective for treating depression?